KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $237.7 million.

  • Charles River Laboratories International's Current Deferred Revenue fell 565.15% to $237.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.7 million, marking a year-over-year decrease of 565.15%. This contributed to the annual value of $283.0 million for FY2024, which is 366.3% up from last year.
  • Latest data reveals that Charles River Laboratories International reported Current Deferred Revenue of $237.7 million as of Q3 2025, which was down 565.15% from $268.3 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Current Deferred Revenue registered a high of $283.0 million during Q4 2024, and its lowest value of $213.0 million during Q1 2021.
  • Its 5-year average for Current Deferred Revenue is $247.9 million, with a median of $250.5 million in 2023.
  • As far as peak fluctuations go, Charles River Laboratories International's Current Deferred Revenue soared by 3574.85% in 2021, and later plummeted by 565.15% in 2025.
  • Charles River Laboratories International's Current Deferred Revenue (Quarter) stood at $219.7 million in 2021, then rose by 20.28% to $264.3 million in 2022, then increased by 3.31% to $273.0 million in 2023, then grew by 3.66% to $283.0 million in 2024, then decreased by 16.0% to $237.7 million in 2025.
  • Its last three reported values are $237.7 million in Q3 2025, $268.3 million for Q2 2025, and $250.5 million during Q1 2025.